3[3]Sieradzko K, Villari P, Tomasz A. Decreased susceptibilities to teicomycin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of Staphylococci.[J]. Antimicrob Agents Chemother, 1998, 42(1): 100
4[4]Poyart C, Pierre C, Quesne G, et al. Emergence of vancomycin resistance in the genus Streptococcus: Characterization of a vanB transferable determinant in Streptococcus bovis, [J]. Antimicrob Agents Chemother, 1997, 41(1):24
5[5]Ligozzi M, Cascio GL, Fontana R. vanA gene cluster in a vancomycin-resistant clinical isolate of Bacillus circulans.[J]. Antimicrob Agents Chemother, 1998, 42(8): 2055
6[6]Parenti F, Cavalleri. Novel glycopeptide antibiotics of the dalbaheptide group. [J]. Drug Fut, 1990, 15(1): 57
7[7]Yan,H-S, Qi D-F, Cheng X-H,et al. Antibiotic activities and affinityes for bacterial cell wall analogue of Ndemethylvancomycin and its derivaties. [J]. J Antibiotics,1998,51(8):750
8[8]Allen NE, LeTourneau D, Hobbs JN. The role of hydrophobic chain as antibacterial activity of semisynthetic glycopeptide antibiotics. [J]. J Antibiotics, 1997, 50(8):675
9[9]Pavlov AY, Berdnikova TF, Olsufyeva EN, et al.Caoboxamides and hydrazide of glycopeptide antibiotic eremomycin synthesis and antibacterial activity. [J]. J Antibiotics, 1996, 49(2): 194
10[10]Linsdell H, Toiron C, Bruix M, et al. Dimerization of A82846B,vancomycin and ristocetin: influence on antibiotic complexation with cell wall model peptides. [J]. J Antibiotics, 1996, 49(2): 181
